Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines

Abstract

These obtained in vitro results are the first effectiveness factors determined for human melanoma at the RA-3 nuclear reactor and show that BNCT dosimetry planning for patients could be successfully performed using these new factors.

Accelerator-based boron neutron capture therapy for malignant glioma: a pilot neutron irradiation study using boron phenylalanine, sodium borocaptate and liposomal borocaptate with a heterotopic U87 glioblastoma model in SCID mice

“…BPA and BSH (Katchem, Prague, Czech Republic), as well as the PEGylated liposomal form of BSH, were used as boron compounds. To prepare the BPA solution, fructose was used in molar excess according to the protocol by Rossini et al (2015). Liposomes were obtained by phase inversion followed by extrusion with the lipid phase of DSPC, DSPE-PEG, and CH used in a 2:1:0.11 molar ratio (Maruyama et al 2004).…”

In-situ formation of holmium oxide in pores of Mesoporous Carbon Nanoparticles as substrates for neutron-activatable radiotherapeutics

“…8b). It has been well established that larger absorbed radiation doses induce a greater tumoricidal effect [21–24]. …”

Simultaneous Observation of Cells and Nuclear Tracks from the Boron Neutron Capture Reaction by UV-C Sensitization of Polycarbonate

“…A concentration of 10 µ g g −1 of boron in the cell culture medium adopted in our study represents a value close to those determined in blood samples during clinical treatment (Fukuda et al, 1994). Furthermore, the 10 µ g g −1 value has been tested in previous studies of effectiveness of BNCT in vitro (Rossini et al, 2015).…”